BiotechTube

MNPR-101-DFO*-89Zr

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Solid Tumor, Adult

Conditions

Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer

Trial Timeline

May 30, 2024 → Apr 1, 2026

NCT ID
NCT06337084

About MNPR-101-DFO*-89Zr

MNPR-101-DFO*-89Zr is a phase 1 stage product being developed by Monopar Therapeutics for Solid Tumor, Adult. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06337084. Target conditions include Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma.

What happened to similar drugs?

5 of 13 similar drugs in Solid Tumor, Adult were approved

Approved (5) Terminated (2) Active (8)
✅DurvalumabAstraZenecaApproved
✅ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zetaRocheApproved
✅denosumab + pamidronateAmgenApproved
✅Sacituzumab Govitecan-hiyGilead SciencesApproved
✅Binimetinib only treatment + Encorafenib only Treatment + Encorafenib & Binimetinib Treatment + Treatment of Encorafenib & Binimetinib & Ribociclib + Treatment of Encorafenib & Binimetinib & CetuximabPfizerApproved
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
🔄MEDI4736 (Durvalumab) + MEDI4736 (Durvalumab) + TremelimumabAstraZenecaPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06337084Phase 1Recruiting

Competing Products

20 competing products in Solid Tumor, Adult

See all competitors
ProductCompanyStageHype Score
ALG.APV-527Alligator Bioscience ABPhase 1/2
18
ATOR-1017Alligator Bioscience ABPhase 1
19
ATOR-1015Alligator Bioscience ABPhase 1
19
mRNA-4359ModernaPhase 2
0
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
mRNA-2416ModernaPhase 2
0
E7050EisaiPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
BBP-398 + sotorasibBridgeBio PharmaPhase 1
18
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
18
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
RC220 + Doxorubicin (Adriamycin)Race OncologyPhase 1
30
BT1718Bicycle TherapeuticsPhase 1/2
22
NL-201 + Pembrolizumab Injection [Keytruda]NeurogenePhase 1
19
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + BevacizumabZentalis PharmaceuticalsPhase 1
26